Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Softwarewmm2021-02-26T19:12:40+00:00November 7th, 2017|2017 プレスリリース, プレスリリース| 続きを読む
Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.wmm2021-02-26T19:12:46+00:00August 1st, 2017|2017 プレスリリース, プレスリリース| 続きを読む
FDA approves new combination treatment for acute myeloid leukemiawmm2021-02-26T19:12:55+00:00April 28th, 2017|2017 プレスリリース, プレスリリース| 続きを読む
Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AMLwmm2021-02-26T19:13:02+00:00April 28th, 2017|2017 プレスリリース, プレスリリース| 続きを読む
Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapieswmm2021-02-26T19:13:49+00:00March 28th, 2017|2017 プレスリリース, プレスリリース| 続きを読む
Invivoscribe Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Softwarewmm2021-02-26T19:13:58+00:00February 28th, 2017|2017 プレスリリース, プレスリリース| 続きを読む
Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kitswmm2021-02-26T19:14:04+00:00February 14th, 2017|2017 プレスリリース, プレスリリース| 続きを読む
Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kitswmm2021-02-26T19:14:11+00:00January 31st, 2017|2017 プレスリリース, プレスリリース| 続きを読む
